Want to see IN:SYNCOMF full AI Analyst Report?
SYNCOMF Stock Chart & Stats
₹13.98
-₹0.26(-1.33%)
At close: 4:00 PM EST
₹13.98
-₹0.26(-1.33%)
Day’s Range― - ―
52-Week Range₹10.21 - ₹19.40
Previous CloseN/A
Volume2.15M
Average Volume (3M)249.72K
Market Cap
₹13.38B
Enterprise Value₹13.32B
Total Cash (Recent Filing)₹1.45B
Total Debt (Recent Filing)₹6.97M
Price to Earnings (P/E)16.2
Beta1.63
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.34
Price to Sales (P/S)1.99
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthThe sharp reduction in debt and very low debt-to-equity materially de-risks the company. Strong equity and minimal leverage increase financial flexibility to fund working capital, capex, or product investments, and improve resilience to industry cycles and funding shocks.
Improved ProfitabilityA sustained rise in net margin indicates stronger earnings power and operating discipline. Higher margins support internal cash generation for reinvestment and buffer against pricing or cost swings, improving the likelihood of durable free cash flow if revenue stabilizes.
Diversified Pharma Revenue StreamsMultiple revenue channels — branded formulations, contract manufacturing and exports — reduce customer and channel concentration risk. This structural diversification permits reallocation of commercial focus if one stream weakens and enables steadier long-term growth opportunities.
Bears Say
Top-line Decline / Growth InconsistencyA falling revenue trend after prior scale-up signals limited sustainable demand or lost market share. Without consistent top-line growth, maintaining higher margins and funding long-term investments becomes harder, constraining durable earnings expansion.
Gross Margin CompressionMaterial gross-margin erosion suggests adverse input costs, pricing pressure, or mix shifts. Lower gross margins reduce operating leverage and leave less room to absorb SG&A or R&D, making sustained net margin gains more vulnerable if revenue weakens.
Cash-flow Volatility And Conversion RiskWhile cash flow rebounded in FY2026, historical negative OCF/FCF years and uneven conversion (OCF only ~55% of net income) indicate volatility. Inconsistent cash generation hampers reliable funding for capex, dividends or working capital and raises execution risk.
Syncom Formulation (India) Ltd. News
SYNCOMF FAQ
What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹10.21 and its highest was ₹19.40 in the past 12 months.
What is Syncom Formulation (India) Ltd.’s market cap?
Syncom Formulation (India) Ltd.’s market cap is ₹13.38B.
When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
Syncom Formulation (India) Ltd.’s upcoming earnings report date is Aug 10, 2026 which is in 34 days.
How were Syncom Formulation (India) Ltd.’s earnings last quarter?
Syncom Formulation (India) Ltd. released its earnings results on May 22, 2026. The company reported ₹0.27 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.27.
Is Syncom Formulation (India) Ltd. overvalued?
According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued.
Does Syncom Formulation (India) Ltd. pay dividends?
Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
What is Syncom Formulation (India) Ltd.’s EPS estimate?
Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncom Formulation (India) Ltd. have?
Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
Syncom Formulation (India) Ltd. reported an EPS of ₹0.27 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.42%.
Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
Currently, no hedge funds are holding shares in IN:SYNCOMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syncom Formulation (India) Ltd.
Established in 1985 and based in Indore, India, Syncom Formulations (India) Limited specializes in the development, marketing, and sale of a wide array of finished pharmaceutical products. The company provides an extensive portfolio addressing numerous therapeutic categories, including but not limited to pain relief, infectious diseases, cardiovascular health, mental well-being, respiratory ailments, and nutritional deficiencies, alongside specific treatments for conditions like gout and erectile dysfunction, encompassing both generic and specialized medicines. These medicinal preparations are available in various formats such as tablets, capsules, oral liquids, injectables (both liquid and dry vial), dry syrups, topical ointments, inhalers, and herbal formulations. In addition to its core pharmaceutical business, Syncom Formulations also engages in commodity trading and property leasing. The company serves the domestic Indian market and actively exports its products globally.
Technical Analysis
Bajaj Healthcare Ltd
―
Indoco Remedies Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Lincoln Pharmaceuticals Ltd
―
Wanbury Limited
―